This indicates that the combination of nab-paclitaxel and a PD-1 inhibitor is safe, consistent with previous studies (Hao et al., 2023), and notably better than first-line chemotherapy for STS (Gronchi et al., 2017; Seddon et al., 2017). The gene discussed is PDCD1; the disease is telomere syndrome.